Carregant...
Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?
INTRODUCTION: Rifabutin, a rifamycin of equivalent potency to rifampicin, has several advantages in its pharmacokinetic and toxicity profile, particularly in HIV co‐infected patients on combined antiretroviral therapy (cART). In this commentary, we evaluate evidence supporting increased global use o...
Guardat en:
| Publicat a: | J Int AIDS Soc |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6637439/ https://ncbi.nlm.nih.gov/pubmed/31318176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jia2.25333 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|